Ankur Shah, MD
Nephrology · Riverside, RINPI 1043653116
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,181 of the $26,561 with a category attached, or 76.0%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 70.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $16,311 and has fallen 95.2% since, to $786 in 2025. Among nephrology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $428.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$19K
- Calliditas Therapeutics US Inc.$5K
- AstraZeneca$2K
- Fresenius USA Marketing, Inc.$802
- Nxstage Medical, Inc.$212
- Otsuka America Pharmaceutical, Inc.$187
- plus $740 from 9 others
Across 36 payments — averaging $8379.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$89K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$81K
- CSL Behring$78K
- Vertex$30K
- Biogen$15K
- Novartis$9K
What the payments were for
- Consulting fees$20,18176%
- Travel & lodging$3,52913%
- Food & beverage$2,85111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 19 | $18,586 |
| Calliditas Therapeutics US Inc. | 7 | $4,525 |
| AstraZeneca(2 entities) | 14 | $1,509 |
| Fresenius USA Marketing, Inc. | 7 | $802 |
| Nxstage Medical, Inc. | 2 | $212 |
| Otsuka America Pharmaceutical, Inc. | 2 | $187 |
| GSK | 2 | $137 |
| Travere Therapeutics, Inc. | 2 | $137 |
| Akebia Therapeutics Inc | 1 | $125 |
| Novo Nordisk | 1 | $123 |
| Vantive US Healthcare LLC | 1 | $116 |
| Cormedix Inc. | 1 | $37 |
| Johnson & Johnson | 1 | $32 |
| Baxter Healthcare | 1 | $19 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$4,402
- FARXIGA$778
- NXSTAGE SYSTEM ONE$131
- LIBERTY SELECT CYCLER$131
- AURYXIA$125
- Vafseo$125
- Ozempic$123
- Renal - PD$116
- BENLYSTA$105
- JYNARQUE$104
How this compares
$26,561 in reported general payments places this provider in the 95th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 23 | $6,815 |
| Torsemide | 24 | $430 |
| Chlorthalidone | 28 | $395 |
| Amlodipine Besylate | 36 | $353 |
| Gabapentin | 18 | $186 |
| Losartan Potassium | 20 | $183 |
| Potassium Chloride | 22 | $179 |
| Carvedilol | 13 | $171 |
| Lisinopril | 18 | $151 |
| Spironolactone | 14 | $98 |
| Furosemide | 14 | $58 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Riverside
- Reginald GohhRiverside$47K
- Jie TangRiverside$23K
- Douglas SheminRiverside$22K
- Kristen TillquistRiverside$2K
- Basma MerhiRiverside$2K
- John ObellRiverside$2K
- Sandipan ShringiRiverside$1K
- George BaylissRiverside$246
- Susie HuRiverside$205
- Matthew LynchRiverside$180
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.